Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
PLoS One. 2011;6(8):e23840. doi: 10.1371/journal.pone.0023840. Epub 2011 Aug 23.
Resistance to anoikis, which is defined as apoptosis induced by loss of integrin-mediated cell attachment to the extracellular matrix, is a determinant of tumor progression and metastasis. We have previously identified the mitochondrial Bit1 (Bcl-2 inhibitor of transcription) protein as a novel anoikis effector whose apoptotic function is independent from caspases and is uniquely controlled by integrins. In this report, we examined the possibility that Bit1 is suppressed during tumor progression and that Bit1 downregulation may play a role in tumor metastasis.
METHODOLOGY/PRINCIPAL FINDINGS: Using a human breast tumor tissue array, we found that Bit1 expression is suppressed in a significant fraction of advanced stages of breast cancer. Targeted disruption of Bit1 via shRNA technology in lowly aggressive MCF7 cells conferred enhanced anoikis resistance, adhesive and migratory potential, which correlated with an increase in active Extracellular kinase regulated (Erk) levels and a decrease in Erk-directed phosphatase activity. These pro-metastasis phenotypes were also observed following downregulation of endogenous Bit1 in Hela and B16F1 cancer cell lines. The enhanced migratory and adhesive potential of Bit1 knockdown cells is in part dependent on their high level of Erk activation since down-regulating Erk in these cells attenuated their enhanced motility and adhesive properties. The Bit1 knockdown pools also showed a statistically highly significant increase in experimental lung metastasis, with no differences in tumor growth relative to control clones in vivo using a BALB/c nude mouse model system. Importantly, the pulmonary metastases of Bit1 knockdown cells exhibited increased phospho-Erk staining.
CONCLUSIONS/SIGNIFICANCE: These findings indicate that downregulation of Bit1 conferred cancer cells with enhanced anoikis resistance, adhesive and migratory properties in vitro and specifically potentiated tumor metastasis in vivo. These results underscore the therapeutic importance of restoring Bit1 expression in cancer cells to circumvent metastasis at least in part through inhibition of the Erk pathway.
失巢凋亡是指整合素介导的细胞与细胞外基质附着的丧失所诱导的细胞凋亡,它是肿瘤进展和转移的决定因素。我们之前已经鉴定出线粒体 Bit1(转录因子 Bcl-2 抑制剂)蛋白是一种新的失巢凋亡效应因子,其凋亡功能不依赖于半胱天冬酶,并且仅受整合素控制。在本报告中,我们研究了 Bit1 在肿瘤进展过程中受到抑制的可能性,以及 Bit1 下调是否在肿瘤转移中发挥作用。
方法/主要发现:我们使用人乳腺癌组织阵列发现,Bit1 表达在乳腺癌的晚期阶段显著受到抑制。在低侵袭性 MCF7 细胞中通过 shRNA 技术靶向敲除 Bit1,赋予了增强的失巢凋亡抗性、黏附和迁移潜能,这与活性细胞外激酶调节的(Erk)水平的增加和 Erk 定向磷酸酶活性的降低相关。在 Hela 和 B16F1 癌细胞系中下调内源性 Bit1 也观察到了这些促转移表型。Bit1 敲低细胞的增强迁移和黏附潜能部分依赖于其高水平的 Erk 激活,因为在这些细胞中下调 Erk 会减弱它们增强的运动和黏附特性。Bit1 敲低池在实验性肺转移中也表现出统计学上显著增加,与体内 BALB/c 裸鼠模型系统中对照克隆相比,肿瘤生长没有差异。重要的是,Bit1 敲低细胞的肺转移显示出增加的磷酸化-Erk 染色。
结论/意义:这些发现表明,Bit1 的下调赋予了癌细胞在体外增强的失巢凋亡抗性、黏附和迁移特性,并特异性增强了体内肿瘤转移。这些结果强调了在癌症细胞中恢复 Bit1 表达以避免转移的治疗重要性,至少部分通过抑制 Erk 通路。